ClearPoint Neuro (CLPT) EBITDA Margin (2011 - 2026)

ClearPoint Neuro has disclosed EBITDA Margin across 15 years of filings, most recently posting 69.9% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 69.9%, up 273.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 65.2% (up 206.0% YoY), and the FY2025 annual result was 65.36%, down 249.0% from the prior year.
• EBITDA Margin came in at 69.9% for Q1 2026 at ClearPoint Neuro, down from 67.68% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 55.19% in Q1 2024 to a low of 119.85% in Q2 2023.
• The 5-year median for EBITDA Margin is 72.53% (2024), against an average of 75.27%.
• Across the five-year window, EBITDA Margin sank 3900 bps in 2023 and soared 5973 bps in 2024, its largest moves.
• ClearPoint Neuro's EBITDA Margin stood at 86.37% in 2022, then gained by 20 bps to 69.1% in 2023, then slipped by 5 bps to 72.53% in 2024, then rose by 7 bps to 67.68% in 2025, then dropped by 3 bps to 69.9% in 2026.
• The last three EBITDA Margin figures came in at 69.9% (Q1 2026), 67.68% (Q4 2025), and 59.54% (Q3 2025), per Business Quant data.